Brokers see upside in Dimerix as phase III kidney disease drug trial progresses

Two brokers point to potential commercial upside for Dimerix as it advances its phase III trial of DMX-200 in focal ... Read More The post Brokers see upside in Dimerix as phase III kidney disease drug trial progresses appeared first on Stockhead .

Go to News Site